orforglipron vs semaglutide New GLP pill, orforglipron, versus established GLP pill, in those with obesity & type 2 diabetes. 1️⃣Average blood sugar improved slightly more with (reduced HbA1c by 2.2% from baseline 8.3%) Daily Oral GLP-1 Receptor Agonist

Pochini L, Galluccio M, Scalise M, Console L, Indiveri C

9: Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM

Clinical research further reinforces the beneficial effects of GLP-1RAs on DPN

Evidence from animal models points toward support of axonal continuity, synaptic stability, and functional recovery following nervous system injury

Global Clinical Lead, Clinical Development, Migraine & Pain Senior Medical Specialist, Therapeutic Areas - Global Clinical Development Director, Drug Safety Operations Medical Writer responsible for Clinical Disclosure Clinical Supply Manager Laboratoriechef Pharma, Kosmetik & Helse, Biofac/1948 Senior Safety Manager International Product Manager, MEQU/1947 Rdgiver og forhandler med flair for pipeline og partnerskaber (Pipeline Insights & Engagement Advisor) - vil du vre med til at sikre fremtidens adgang til nye lgemidler

It will track how therapies are used in practice, how long GLP-1 drugs have become the hottest drug class in a generation, driven by an obesity epidemic affecting 40% of American adults and linked to diabetes, heart disease and a growing list of other conditions